52% of innovations approved in 2020 have some limitation in their prescription or dispensing El 52% de las innovaciones aprobadas en 2020 tienen alguna limitación a la prescripción o la dispensación Omakase2021-02-10T12:16:21+00:00February 10th, 2021|News & Events| Share This Article LinkedInEmail Related Posts MCDA methodology in the Farmacia Hospitalaria journal MCDA methodology in the Farmacia Hospitalaria journal July 6th, 2022 Alicia Gil, CEO Omakase Consulting attended a session held in the Spanish National Congress organised by FEDER (Spanish Rare Diseases Organisation) Alicia Gil, CEO Omakase Consulting attended a session held in the Spanish National Congress organised by FEDER (Spanish Rare Diseases Organisation) June 29th, 2022 The new update in the information system BIFIMED from the Spanish Ministry of Health The new update in the information system BIFIMED from the Spanish Ministry of Health June 28th, 2022 Omakase Consulting keeps growing! Omakase Consulting keeps growing! June 22nd, 2022 The AEMPS, recognised with the 2021 Public Health Figure award granted by Fundamed & Wecare-u The AEMPS, recognised with the 2021 Public Health Figure award granted by Fundamed & Wecare-u July 9th, 2021 | 0 Comments Revalmed Coordination Group meeting May 2021 Revalmed Coordination Group meeting May 2021 June 25th, 2021 | 0 Comments Updated Annual Report on Orphan Drugs authorised in Spain and approved by the European Commission between 2003 & 2020 Updated Annual Report on Orphan Drugs authorised in Spain and approved by the European Commission between 2003 & 2020 April 9th, 2021 | 0 Comments Alicia Gil, miembro de SWL Alicia Gil, miembro de SWL March 26th, 2021 | 0 Comments Leave A Comment Cancel reply Comment Save my name, email, and website in this browser for the next time I comment.
Leave A Comment